Compare PERF & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERF | CNTN |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Taiwan | United States |
| Employees | 353 | 3 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.1M | 184.2M |
| IPO Year | N/A | 2022 |
| Metric | PERF | CNTN |
|---|---|---|
| Price | $1.67 | $3.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 297.4K | ★ 559.6K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.93 | N/A |
| Revenue Next Year | $9.44 | N/A |
| P/E Ratio | $26.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $2.98 |
| 52 Week High | $2.67 | $5.27 |
| Indicator | PERF | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 44.50 |
| Support Level | $1.57 | $3.11 |
| Resistance Level | $1.85 | $3.51 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 66.67 | 63.08 |
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.